Acceleron Pharma Inc (NASDAQ:XLRN) EVP John D. Quisel sold 3,584 shares of the stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $45.23, for a total value of $162,104.32. Following the completion of the transaction, the executive vice president now owns 59,158 shares of the company’s stock, valued at approximately $2,675,716.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ:XLRN traded up $0.31 on Tuesday, reaching $45.81. 266,800 shares of the stock traded hands, compared to its average volume of 369,340. The company has a current ratio of 17.11, a quick ratio of 17.11 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $2.35 billion, a price-to-earnings ratio of -17.69 and a beta of 1.22. Acceleron Pharma Inc has a 12 month low of $37.01 and a 12 month high of $59.59. The company’s fifty day simple moving average is $44.26 and its 200 day simple moving average is $42.87.
Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 29.51% and a negative net margin of 318.84%. The firm had revenue of $27.67 million during the quarter, compared to the consensus estimate of $28.72 million. During the same quarter in the prior year, the company posted ($0.63) EPS. The company’s quarterly revenue was up 649.9% on a year-over-year basis. Equities analysts anticipate that Acceleron Pharma Inc will post -2.33 EPS for the current fiscal year.
Several brokerages have commented on XLRN. ValuEngine raised Acceleron Pharma from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 8th. Citigroup reaffirmed a “buy” rating and set a $66.00 target price on shares of Acceleron Pharma in a research note on Friday, May 24th. Goldman Sachs Group reiterated a “neutral” rating and set a $54.00 target price on shares of Acceleron Pharma in a report on Wednesday, May 29th. Zacks Investment Research reissued a “hold” rating on shares of Acceleron Pharma in a research report on Saturday, July 20th. Finally, Morgan Stanley set a $53.00 price target on Acceleron Pharma and gave the stock a “hold” rating in a research report on Monday, July 15th. Six analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $60.10.
About Acceleron Pharma
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Featured Story: Bull Market
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.